Literature DB >> 8504624

Plasma concentrations and renal clearance of morphine, morphine-3-glucuronide and morphine-6-glucuronide in cancer patients receiving morphine.

A A Somogyi1, R L Nation, C Olweny, P Tsirgiotis, J van Crugten, R W Milne, J F Cleary, C Danz, F Bochner.   

Abstract

The plasma concentrations and renal clearance values of morphine, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) were determined in 11 adult cancer patients maintained on a long term oral morphine dosage (10 to 100mg every 4h). Concentrations in plasma and urine were determined by a specific high performance liquid chromatography assay. In this group of patients, whose creatinine clearance values ranged from 52 to 180 ml/min (3.12 to 10.8 L/h), average steady-state plasma concentrations of morphine, M3G and M6G were related (p < 0.01) to the morphine dose per kilogram of bodyweight. The mean total urinary recovery as morphine, M3G and M6G was 74.6 +/- 26.5% of the dose. Renal clearance values for M3G and M6G were closely related (r2 = 0.80; p < 0.0005). It was not possible to detect a relationship between the renal clearance of morphine, M3G and M6G, and that of creatinine. The renal tubular handling of all 3 compounds showed wide interindividual variation, and there was evidence of either net renal tubular secretion or reabsorption. There was no apparent relationship between plasma morphine and M6G concentrations and pain relief.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8504624     DOI: 10.2165/00003088-199324050-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  29 in total

1.  Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite.

Authors:  D Paul; K M Standifer; C E Inturrisi; G W Pasternak
Journal:  J Pharmacol Exp Ther       Date:  1989-11       Impact factor: 4.030

2.  Long lasting respiratory depression induced by morphine-6-glucuronide?

Authors:  J Hasselström; U Berg; A Löfgren; J Säwe
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of morphine.

Authors:  P A Glare; T D Walsh
Journal:  Ther Drug Monit       Date:  1991-01       Impact factor: 3.681

4.  Analgesic effect of morphine glucuronides.

Authors:  K Shimomura; O Kamata; S Ueki; S Ida; K Oguri; H Yoshimura; H Tsukamoto
Journal:  Tohoku J Exp Med       Date:  1971-09       Impact factor: 1.848

5.  Renal tubular transport of morphine, morphine-6-glucuronide, and morphine-3-glucuronide in the isolated perfused rat kidney.

Authors:  J T Van Crugten; B C Sallustio; R L Nation; A A Somogyi
Journal:  Drug Metab Dispos       Date:  1991 Nov-Dec       Impact factor: 3.922

6.  Pharmacokinetic drug interactions between triamterene and ranitidine in humans: alterations in renal and hepatic clearances and gastrointestinal absorption.

Authors:  M Muirhead; F Bochner; A Somogyi
Journal:  J Pharmacol Exp Ther       Date:  1988-02       Impact factor: 4.030

7.  Oral morphine in cancer patients: in vivo kinetics and in vitro hepatic glucuronidation.

Authors:  J Säwe; L Kager; J O Svensson Eng; A Rane
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

8.  The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients.

Authors:  R W Milne; R L Nation; A A Somogyi; F Bochner; W M Griggs
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

9.  Morphine-6-glucuronide: analgesic effects and receptor binding profile in rats.

Authors:  F V Abbott; R M Palmour
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

10.  Relative bioavailability of controlled release morphine tablets (MST continus) in cancer patients.

Authors:  P Poulain; P J Hoskin; G W Hanks; O A-Omar; V A Walker; A Johnston; P Turner; G W Aherne
Journal:  Br J Anaesth       Date:  1988-11       Impact factor: 9.166

View more
  10 in total

1.  Flexible dosing of tincture of opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics.

Authors:  Andrew A Somogyi; Mie Larsen; Reza M Abadi; Jaroon Jittiwutikarn; Robert Ali; Jason M White
Journal:  Br J Clin Pharmacol       Date:  2008-11       Impact factor: 4.335

Review 2.  Opioid Management in Older Adults with Chronic Kidney Disease: A Review.

Authors:  Montgomery T Owsiany; Chelsea E Hawley; Laura K Triantafylidis; Julie M Paik
Journal:  Am J Med       Date:  2019-07-08       Impact factor: 4.965

Review 3.  The use of opioids in cancer patients with renal impairment-a systematic review.

Authors:  Tonje A Sande; Barry J A Laird; Marie T Fallon
Journal:  Support Care Cancer       Date:  2016-10-15       Impact factor: 3.603

Review 4.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

5.  Morphine and morphine-glucuronide concentrations in plasma and CSF during long-term administration of oral morphine.

Authors:  R T van Dongen; B J Crul; P M Koopman-Kimenai; T B Vree
Journal:  Br J Clin Pharmacol       Date:  1994-09       Impact factor: 4.335

6.  Rectal administration of nicomorphine in patients improves biological availability of morphine and its glucuronide conjugates.

Authors:  P M Koopman-Kimenai; T B Vree; L H Booij; R Dirksen
Journal:  Pharm World Sci       Date:  1994-12-02

7.  Heroin crystal nephropathy.

Authors:  Josef Edrik Keith Bautista; Basma Merhi; Oliver Gregory; Susie Hu; Kammi Henriksen; Reginald Gohh
Journal:  Clin Kidney J       Date:  2015-03-31

8.  Population Pharmacokinetics of Morphine in Patients With Nonalcoholic Steatohepatitis (NASH) and Healthy Adults.

Authors:  V Pierre; C K Johnston; B C Ferslew; Klr Brouwer; D Gonzalez
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-04-18

9.  A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients.

Authors:  Astrid W Oosten; João A Abrantes; Siv Jönsson; Maja Matic; Ron H N van Schaik; Peter de Bruijn; Carin C D van der Rijt; Ron H J Mathijssen
Journal:  Clin Pharmacokinet       Date:  2017-07       Impact factor: 6.447

10.  Bridging the gap between in silico and in vivo by modeling opioid disposition in a kidney proximal tubule microphysiological system.

Authors:  Tomoki Imaoka; Weize Huang; Sara Shum; Dale W Hailey; Shih-Yu Chang; Alenka Chapron; Catherine K Yeung; Jonathan Himmelfarb; Nina Isoherranen; Edward J Kelly
Journal:  Sci Rep       Date:  2021-11-01       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.